Registry for Patients With and Without Heart Failure
Preserved vs. Reduced Ejection Fraction Biomarker Registry and Precision Medicine Database for Ambulatory Heart Failure Patients (PREFER-HF) Study
This study is looking to understand different types of heart failure by gathering health information from people aged 18 and older, both with and without the condition, to improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT03480633 on ClinicalTrials.gov |
What this trial studies
This observational registry aims to comprehensively examine clinical characteristics, proteomic, metabolomic, genomic, and imaging data to understand the development and progression of different types of heart failure. Patients aged 18 and older, both with and without heart failure, will be enrolled to evaluate distinct heart failure phenotypes and cardiomyopathies, including amyloidosis. The study will collect baseline and one-year follow-up data, including blood samples and clinical outcomes, to optimize precision medicine in heart failure treatment.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a history of clinical symptoms consistent with heart failure.
Not a fit: Patients with end-stage renal disease on dialysis may not receive any benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatments for patients with heart failure.
How similar studies have performed: Other studies have shown success in using similar approaches to improve understanding and treatment of heart failure, indicating this study builds on established methodologies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria for patients with HF: * 18 years and older * History of clinical symptoms consistent with HF and at least one of the following supporting evidence of HF: * NT-proBNP \> 125 pg/mL * BNP \> 35 pg/mL * Capillary wedge pressure ≥ 15 mmHg on right heart catheterization or CI \<2.8 L/min/m2 * LVEDP ≥ 15 mmHg * Radiographic evidence of pulmonary edema * Improvement in symptoms with diuretic initiation of increase * CPET evidence of cardiac etiology of symptoms HFpEF: LVEF ≥ 50% HFrEF: LVEF \<50% Exclusion criteria (for all patients, including both those with HFpEF and HFrEF): \- End stage renal disease on dialysis
Where this trial is running
Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Hanna Gaggin, MD, MPH — Massachusetts General Hospital
- Study coordinator: Abbie Macher, BS
- Email: ajmacher@mgh.harvard.edu
- Phone: 617-643-6328
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.